Search: (WFRF:(Blaxhult A)) srt2:(2010-2014)
> (2013) >
Lopinavir/ritonavir...
Lopinavir/ritonavir, atazanavir/ritonavir, and efavirenz in antiretroviral-naïve HIV-1-infected individuals over 144 weeks: An open-label randomized controlled trial.
-
- Andersson, Lars-Magnus, 1968 (author)
- Gothenburg University,Göteborgs universitet,Institutionen för biomedicin, avdelningen för infektionssjukdomar,Institute of Biomedicine, Department of Infectious Medicine
-
- Vesterbacka, J. (author)
- Karolinska Institutet
-
- Blaxhult, Anders (author)
- Karolinska Institutet
-
show more...
-
- Flamholc, Leo (author)
- Lund University,Lunds universitet,Enheten för infektionssjukdomar,Forskargrupper vid Lunds universitet,Infectious Diseases Research Unit,Lund University Research Groups
-
- Nilsson, Staffan, 1956 (author)
- Gothenburg University,Göteborgs universitet,Institutionen för matematiska vetenskaper, matematisk statistik,Department of Mathematical Sciences, Mathematical Statistics
-
- Ormaasen, Vidar (author)
- Oslo universitetssykehus,Oslo University Hospital
-
- Sonnerborg, A. (author)
- Karolinska Institutet
-
- Gisslén, Magnus, 1962 (author)
- Gothenburg University,Göteborgs universitet,Institutionen för biomedicin, avdelningen för infektionssjukdomar,Institute of Biomedicine, Department of Infectious Medicine
-
show less...
-
(creator_code:org_t)
- 2013-01-07
- 2013
- English.
-
In: Scandinavian Journal of Infectious Diseases. - : Informa UK Limited. - 0036-5548 .- 1651-1980. ; 45:7, s. 543-551
- Related links:
-
http://dx.doi.org/10...
-
show more...
-
https://doi.org/10.3...
-
https://research.cha...
-
https://lup.lub.lu.s...
-
https://gup.ub.gu.se...
-
http://kipublication...
-
show less...
Abstract
Subject headings
Close
- Background: The objective of this study was to compare the efficacy of ritonavir boosted atazanavir versus ritonavir boosted lopinavir or efavirenz, all in combination with 2 nucleoside analogue reverse transcriptase inhibitors (NRTIs), over 144 weeks in antiretroviral-naïve HIV-1-infected individuals. Methods: A prospective open-label randomized controlled trial was conducted at 29 sites in Sweden and Norway between April 2004 and December 2009. Patients were randomized to receive either efavirenz 600 mg once daily (EFV), or atazanavir 300 mg and ritonavir 100 mg once daily (AZV/r), or lopinavir 400 mg and ritonavir 100 mg twice daily (LPV/r). The primary endpoints were the proportion of patients with HIV-1 RNA 100,000 copies/ml at baseline had similar response rates in all arms. Conclusion: EFV was superior to LPV/r at week 48, but there were no significant differences between the 3 arms in the long-term (144 weeks) follow-up.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Infektionsmedicin (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Infectious Medicine (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Medicinska och farmaceutiska grundvetenskaper -- Immunologi inom det medicinska området (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Basic Medicine -- Immunology in the medical area (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Medicinska och farmaceutiska grundvetenskaper -- Farmakologi och toxikologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Basic Medicine -- Pharmacology and Toxicology (hsv//eng)
Keyword
- treatment-naive patients
- randomized controlled trial
- HIV-1
- Combination antiretroviral therapy
- Combination antiretroviral therapy
- HIV-1
- treatment-naive patients
- randomized controlled trial
- Combination antiretroviral therapy; HIV-1; treatment-naive patients; randomized controlled trial
Publication and Content Type
- art (subject category)
- ref (subject category)
Find in a library
To the university's database